XTLB
XTL Biopharmaceuticals Ltd.
1W: +13.9%
1M: +238.8%
3M: +235.4%
YTD: +352.0%
1Y: +137.7%
3Y: +120.3%
5Y: -19.6%
$2.63
-0.08 (-2.95%)
After Hours: $2.66 (+0.03, +0.95%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.9M
52W Range0.53-2.9592
Volume55,520
Avg Volume736,361
Beta0.73
Dividend—
Analyst Ratings
Company Info
CEONoam Band
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2005-09-01
Websitextlbio.com
5 Badner Street
Ramat Gan 5218102
IL
Ramat Gan 5218102
IL
972 3 611 6600
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hillel Fain Osnat | 1,000,000 | $0.01 | 2026-03-18 | |
| Segal Niv | 0 | — | 2026-03-18 | |
| EDELMAN JOSEPH | S-Sale | 9,600,000 | $0.15 | 2008-11-19 |
| EDELMAN JOSEPH | S-Sale | 24,681,360 | $0.14 | 2008-11-18 |
| EDELMAN JOSEPH | S-Sale | 29,740 | $0.16 | 2008-11-18 |